Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress

Interest in the H₃R field is still high and has remained almost unchanged over the last 10 years in the number of publications, but the type of publications has changed (fewer new ligands, more pharmacological studies). Currently, the search for new H₃R ligands is focused on multi-target compounds. The first crystal structure of H₃R with a ligand appeared. New therapeutic indications, such as autism, fatigue, and Prader-Willi syndrome, are verified in clinical trials.